##Batrakoulis A, Sorace P, Sakkas GK. Exercise Training with Chronic Kidney Disease. ACSM's Health & Fitness Journal. 2025 Nov 1;29(6):63-6. ##Bimonte VM, Fittipaldi S, Marocco C, Emerenziani GP, Fornari R, Guidetti L, et al. Physical activity and hypocaloric diet recovers osteoblasts homeostasis in women affected by abdominal obesity. Endocrine. 2017;58:340-8. ##Bolboli L, Khajehlandi M. The Effect of Six Weeks of Moderate-Intensity Endurance Training on Serum Levels of Klotho and Expression of the Fibroblast-23 Growth Factor Gene (FGF23) in the Hearts of Diabetic Rats: An Experimental Study. Journal of Rafsanjan University of Medical Sciences. 2021;20(4):371-86. ##Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper H, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. The Cochrane database of systematic reviews. 2002(3):CD000333-CD. ##Cardoso DF, Marques EA, Leal DV, Ferreira A, Baker LA, Smith AC, Viana JL. Impact of physical activity and exercise on bone health in patients with chronic kidney disease: a systematic review of observational and experimental studies. BMC Nephrol. 2020;21:1-11. ##Cejka D, Parada-Rodriguez D, Pichler S, Marculescu R, Kramer I, Kneissel M, et al. Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease. Kidney international. 2016;90(4):828-34. ##Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017;96:29-37. ##Desbiens L-C, Sidibé A, Ung R-V, Fortier C, Munger M, Wang Y-P, et al. FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study. Osteoporosis International. 2018;29:2345-53. ##Elmenyawi AAI, Hassan A. Role of sclerostin, fibroblast growth factor-23, and Klotho in hemodialysis patients. Journal of Medicine in Scientific Research. 2019;2(1):8. ##fazeli v, Motamedi P, Rajabi H, Khaledi N. The Effect Of Combined Training On Aortic Atherosclerosis And FGF23 In Male Rats With Chronic Renal Failure. Research in Sport Medicine and Technology. 2023;21(26):129-40. ##Gonçalves FLC, Elias RM, Dos Reis LM, Graciolli FG, Zampieri FG, Oliveira RB, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol. 2014;15:1-7. ##Hatakeyama J, Inoue S, Li C, Takamura D, Jiang H, Kuroki H, Moriyama H. Effects of acute-and long-term aerobic exercises at different intensities on bone in mice. Journal of Bone and Mineral Metabolism. 2024:1-11. ##Holdsworth G, Roberts SJ, Ke HZ. Novel actions of sclerostin on bone. J Mol Endocrinol. 2019;62(2):R167-R85. ##Janik M, Stuss M, Michalska-Kasiczak M, Jegier A, Sewerynek E. Effects of physical activity on sclerostin concentrations. Endokrynol Pol. 2018;69 (2): 142-149. ##Jürimäe J, Karvelyte V, Remmel L, Tamm A-L, Purge P, Gruodyte-Raciene R, et al. Serum sclerostin concentration is associated with specific adipose, muscle and bone tissue markers in lean adolescent females with increased physical activity. Journal of Pediatric Endocrinology and Metabolism. 2021;34(6):755-61. ##Lima F, El-Husseini A, Monier-Faugere M-C, David V, Mawad H, Quarles D, Malluche HH. FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis. Clin Nephrol. 2014;82(5):287. ##Lima F, Monier-Faugere M-C, Mawad H, David V, Malluche HH. FGF-23 and sclerostin in serum and bone of CKD patients. Clin Nephrol. 2023;99(5):209. ##Luziani S, Candy H, Angraini R, Darma P, Juniari S, Juhanna IV, Adiatmika IPG. Effect of exercise on sclerostin concentrations in blood serum. Sport Fit J. 2022;10:138-47. ##Marques EA, Mota J, Carvalho J. Exercise effects on bone mineral density in older adults: a meta-analysis of randomized controlled trials. Age. 2012;34: 1493-1515 ## Neves RV, Corrêa HL, Deus LA, Reis AL, Souza MK, Simões HG, et al. Dynamic not isometric training blunts osteo-renal disease and improves the sclerostin/FGF23/Klotho axis in maintenance hemodialysis patients: a randomized clinical trial. Journal of Applied Physiology. 2021;130(2):508-16. ##Oniszczuk A, Kaczmarek A, Kaczmarek M, Ciałowicz M, Arslan E, Silva AF, et al. Sclerostin as a biomarker of physical exercise in osteoporosis: A narrative review. Frontiers in endocrinology. 2022;13:954895. ##Ott SM. Bone cells, sclerostin, and FGF23: what’s bred in the bone will come out in the flesh. Kidney international. 2015;87(3):499-501. ##Pickering M-E, Simon M, Sornay-Rendu E, Chikh K, Carlier M-C, Raby A-L, et al. Serum sclerostin increases after acute physical activity. Calcified tissue international. 2017;101:170-3. ##Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. Journal of Biological Chemistry. 2008;283(9):5866-75. ##Rokhsati S, Souri R, Shabkhiz F, Rabbani S, Shahsavari Z. Effect of High Intensity Interval Training on the Level of Atrial Fibrillation, Fibroblast Growth Factor 23 and Klotho Protein in Male Rats with Renal Failure. The Journal of Shahid Sadoughi University of Medical Sciences. 2020;28(5):2660-72. ##Salhab N, Karavetian M, Kooman J, Fiaccadori E, El Khoury CF. Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis. Journal of nephrology. 2019;32:549-66. ##Sharifi M, Ereifej L, Lewiecki EM. Sclerostin and skeletal health. Reviews in Endocrine and Metabolic Disorders. 2015;16:149-56. ##Thompson WR, Ozemek C. ACSM's clinical exercise physiology. Lippincott Williams & Wilkins; 2023 Nov 16. ##Turoń-Skrzypińska A, Mińko A, Rył A, Mańkowska K, Ciechanowski K, Bereda Z, et al. Impact of Effectiveness of Physical Activity in a Virtual Environment on the Regulation of Sclerostin and Interleukin 6 Levels in Haemodialysis Patients. Journal of Clinical Medicine. 2024;13(8):2321. ##Wannenes F, Papa V, Greco EA, Fornari R, Marocco C, Baldari C, et al. Abdominal Fat and Sarcopenia in Women Significantly Alter Osteoblasts Homeostasis In Vitro by a WNT/β‐Catenin Dependent Mechanism. International Journal of Endocrinology; 2014(1):278316. ##Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. Journal of the American Society of Nephrology: JASN. 2011;22(5):956. ##Yavropoulou MP, Xygonakis C, Lolou M, Karadimou F, Yovos JG. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis. Hormones. 2014;13(4):476-87. ##
)